Active Ingredient History

  • Now
Tositumomab is a murine monoclonal antibody which targets the CD20 antigen produced in mammalian cell. It was combined with iodine-131 to produce a radiopharmaceutical for unsealed source radiotherapy, Iodine-131 Tositumomab, for the treatment of non-Hodgkins lymphoma. It is classified as a IgG2a lambda antibody.   Wikipedia

More Chemistry
  • Mechanisms of Action:
  • Multi-specific: No
  • Payload: 131-iodine
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No
131i anti-b1 | 131i-anti-b1 | 131i tositumomab | 131i-tositumomab | anti-b1 antibody i-131 | bexxar | i-131 anti-b1 antibody | i-131 tositumomab | iodine-131 anti-b1 antibody | iodine-131 anti-b1 monoclonal antibody | iodine (131i) tositumomab | iodine-131-labeled anti-cd20 antibody | iodine-131 tositumomab | iodine-131-tositumomab | iodine i 131 tositumomab | tositumomab | tositumomab conjugate with 131i | tositumomab i-131 | tositumomab iodine-131


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue